Company Overview of Weill Cornell Medical College, New York
Weill Cornell Medical College, New York is an educational institution.
525 East 68th Street
New York, NY 10065
Key Executives for Weill Cornell Medical College, New York
Weill Cornell Medical College, New York does not have any Key Executives recorded.
Weill Cornell Medical College, New York Key Developments
Weill Cornell Medical College, New York Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 05:00 PM
Jan 6 16
Weill Cornell Medical College, New York Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 05:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Christopher Mason, Associate Professor.
Agilent Technologies Inc. Collaborates with Weill Cornell Medical College, in New York, to Advance Research in Amyotrophic Lateral Sclerosis
Sep 4 15
Agilent Technologies Inc. has announced that it is collaborating with Weill Cornell Medical College, in New York, to advance research in amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Agilent will provide the latest mass spectrometry technology to support in research, working toward an understanding of how the most common form of this disease develops in the body. The Agilent 6230B LC TOF and 6550A LC Q-TOF mass spectrometers will be housed in the laboratory of Dr. Steven Gross.
Weill Cornell Medical College and Cellectis Announces Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia
Jun 2 15
Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The alliance will foster the development of Cellectis lead product candidate in AML, called UCART123. The collaboration combines Weill Cornell's broad expertise and resources in translational stem cell science and developmental therapeutics with Cellectis work in development and manufacturing of gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor. The research will be led by co-principal investigators Dr. Gail J. Roboz, director of the leukemia program and an associate professor of medicine at Weill Cornell, and Dr. Monica Guzman, an assistant professor of pharmacology in medicine at Weill Cornell. Dr. Roboz is an internationally recognized leader in the field of acute leukemia and will design and implement clinical testing of UCART123 in patients with AML. Dr. Guzman is a renowned leukemia stem cell biologist who specializes in preclinical and early-stage testing to optimize the development of stem cell-targeted cancer drugs. The alliance will seek to accelerate the development of Cellectis UCART123 in AML. Cellectis proprietary allogeneic CAR T-cell platform utilizes T-cells (immune cells) from healthy donors. The T-cells are engineered with a Chimeric Antigen Receptor (CAR), which enables them to detect specific proteins (antigens) expressed on malignant tumors. Large numbers of allogeneic CAR-modified T-cells are grown in the laboratory and then infused into a patient. The enhanced cells are designed to recognize and attack stem cells harboring the CD123 antigen, which is present on AML blast and stem cells. To enhance safety and minimize toxicity for patients, the company's gene-editing process features customized control properties that seek to prevent the T cells from inappropriately attacking healthy tissues.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|